Risankizumab is a humanized IgG monoclonal antibody that binds with high affinity and specificity to the p19 subunit and selectively inhibits IL-23, critical for psoriatic inflammation. In phase-3 trials (UltIMMa-1, UltIMMa-2, and IMMvent) risankizumab demonstrated early and sustained efficacy at 12-week dosing in patients with moderate-to-severe psoriasis.1,2 To date, limited real-life data are available on its effectiveness and safety.
Hansel, K., Zangrilli, A., Bianchi, L., Peris, K., Chiricozzi, A., Offidani, A., et al. (2021). A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 35(3), 169-170 [10.1111/jdv.17003].
A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic
Zangrilli, A;Bianchi, L;
2021-10-20
Abstract
Risankizumab is a humanized IgG monoclonal antibody that binds with high affinity and specificity to the p19 subunit and selectively inhibits IL-23, critical for psoriatic inflammation. In phase-3 trials (UltIMMa-1, UltIMMa-2, and IMMvent) risankizumab demonstrated early and sustained efficacy at 12-week dosing in patients with moderate-to-severe psoriasis.1,2 To date, limited real-life data are available on its effectiveness and safety.| File | Dimensione | Formato | |
|---|---|---|---|
|
hansel risankizumab.pdf
solo utenti autorizzati
Tipologia:
Documento in Pre-print
Licenza:
Copyright dell'editore
Dimensione
4.13 MB
Formato
Adobe PDF
|
4.13 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
